EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Polymorphisms of MTHFR Associated with Higher Relapse/Death Ratio and Delayed Weekly MTX Administration in Pediatric Lymphoid Malignancies

Hiroko Fukushima, Takashi Fukushima, Aiko Sakai, Ryoko Suzuki, Ryoko Nakajima-Yamaguchi, Chie Kobayashi, Atsushi Iwabuchi, Makoto Saito, Ai Yoshimi, Tomohei Nakao, Keisuke Kato, Masahiro Tsuchida und 5 weitere

Leukemia Research and Treatment · 2013

DOI: 10.1155/2013/238528 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Leukemia Research and Treatment, 2013. Verfasst von Hiroko Fukushima und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child Health, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds . Outcome of childhood malignancy has been improved mostly due to the advances in diagnostic techniques and treatment strategies. While methotrexate (MTX) related polymorphisms have been under investigation in childhood malignancies, many controversial results have been offered.

Objectives

To evaluate associations of polymorphisms related MTX metabolisms and clinical course in childhood lymphoid malignancies.

Method

Eighty-two acute lymphoblastic leukemia and 21 non-Hodgkin’s lymphoma children were enrolled in this study. Four single nucleotide polymorphisms in 2 genes ( MTHFR (rs1801133/c.677C>T/p.Ala222Val and rs1801131/c.1298A>C/p.Glu429Ala) and SLCO1B1 (rs4149056/c.521T>C/p.V174A and rs11045879/c.1865+4846T>C)) were genotyped by Taqman PCR method or direct sequencing. Clinical courses were reviewed retrospectively.

Results

No patient who had the AC/CC genotype of rs1801131 ( MTHFR ) had relapsed or died, in which distribution was statistically different among the AA genotype of rs1801131 ( P = 0.004 ). Polymorphisms of SLCO1B1 (rs11045879 and rs4149056) were not correlated with MTX concentrations, adverse events, or disease outcome.

Conclusions

Polymorphisms of MTHFR (rs1801131) could be the plausive candidate for prognostic predictor in childhood lymphoid malignancies.

Autor:innen und Institutionen

  • Department of Child Health, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
  • Department of Pediatrics, University of Tsukuba Hospital, Japan.
  • Department of Hematology/Oncology, Ibaraki Children's Hospital, Japan.
  • Department of Epidemiology, Faculty of Medicine, University of Tsukuba, Japan.
  • Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Japan.
  • Department of Genetics, Faculty of Medicine, University of Tsukuba, Japan.

Zitieren

APA

Fukushima, H., Fukushima, T., Sakai, A., Suzuki, R., Nakajima-Yamaguchi, R., Kobayashi, C., Iwabuchi, A., Saito, M., Yoshimi, A., Nakao, T., Kato, K., Tsuchida, M., Takahashi, H., Koike, K., Kiyokawa, N., Noguchi, E., & Sumazaki, R. (2013). Polymorphisms of MTHFR Associated with Higher Relapse/Death Ratio and Delayed Weekly MTX Administration in Pediatric Lymphoid Malignancies. Leukemia Research and Treatment. https://doi.org/10.1155/2013/238528

Vancouver

Fukushima H, Fukushima T, Sakai A, Suzuki R, Nakajima-Yamaguchi R, Kobayashi C, et al. Polymorphisms of MTHFR Associated with Higher Relapse/Death Ratio and Delayed Weekly MTX Administration in Pediatric Lymphoid Malignancies. Leukemia Research and Treatment. 2013. doi:10.1155/2013/238528

BibTeX
@article{Fukushima2013,
  author = {Fukushima, Hiroko and Fukushima, Takashi and Sakai, Aiko and Suzuki, Ryoko and Nakajima-Yamaguchi, Ryoko and Kobayashi, Chie and Iwabuchi, Atsushi and Saito, Makoto and Yoshimi, Ai and Nakao, Tomohei and Kato, Keisuke and Tsuchida, Masahiro and Takahashi, Hideto and Koike, Kazutoshi and Kiyokawa, Nobutaka and Noguchi, Emiko and Sumazaki, Ryo},
  title = {Polymorphisms of MTHFR Associated with Higher Relapse/Death Ratio and Delayed Weekly MTX Administration in Pediatric Lymphoid Malignancies},
  journal = {Leukemia Research and Treatment},
  year = {2013},
  doi = {10.1155/2013/238528}
}
Kostenlos starten →